PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
50 hedge funds and large institutions have $60M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Holders
50
Holding in Top 10
1
Calls
$61K
Puts
–
Top Buyers
| 1 | +$682K | |
| 2 | +$622K | |
| 3 | +$267K | |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$237K |
| 5 |
BlackRock
New York
|
+$213K |
Top Sellers
| 1 | -$2.77M | |
| 2 | -$2.46M | |
| 3 | -$605K | |
| 4 |
Millennium Management
New York
|
-$525K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$406K |